37 completed, 3 recruiting, 1 active not recruiting, 1 withdrawn. 42 Phase 1, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 42 | Completed 37, Recruiting 3, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 12 | Completed 9, Active not recruiting 1, Recruiting 1, Withdrawn 1 |
Follow PATH: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Shigella Sonnei 53G Human Infection Study in Kenyan Adults Shigella sonnei 53G, Ciprofloxacin 500 mg - Shigellosis | Phase 1 | Recruiting | University of Oxford | 70 | 2025-01-21 | 2025-03-13 |
| Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Novel oral poliomyelitis vaccine type 1 (nOPV1), Novel oral poliomyelitis vaccine type 2 (nOPV2), Novel oral poliomyelitis vaccine type 3 (nOPV3) - Poliomyelitis | Phase 1 / Phase 2 | Recruiting | PATH | 2400 | 2024-11-20 | 2025-06-03 |
| Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age. IVT GBS-06, Placebo - Group B Streptococcal Infections | Phase 1 / Phase 2 | Active not recruiting | Inventprise Inc. | 600 | 2024-11-12 | 2025-11-18 |
| InvaplexAR-Detox and DmLT Adjuvant in the Netherlands and Zambia 2.5 μg InvaplexAR-Detox, 10 μg InvaplexAR-Detox, 0.1 μg of dmLT - Shigellosis, Bacillary Dysentery | Phase 1 | Recruiting | Leiden University Medical Center | 85 | 2024-10-10 | 2024-11-07 |
| Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine IVT PCV-25, PCV 20 - Pneumococcal Vaccines | Phase 1 | Completed | Inventprise Inc. | 65 | 2022-09-28 | 2023-08-30 |
| Controlled Human Infection Model Challenge/Rechallenge Shigella sonnei 53G, Shigella flexneri 2a 2457T - Shigellosis | Phase 1 | Completed | PATH | 46 | 2022-04-26 | 2025-01-31 |
| Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines Novel Oral Polio Vaccine Type 1 (nOPV1), Novel Oral Polio Vaccine Type 3 (nOPV3), Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1) - Poliomyelitis | Phase 1 | Completed | PATH | 226 | 2021-03-26 | 2024-11-20 |
| Safety and Immunogenicity of a Nipah Virus Vaccine HeV-sG-V, Normal Saline Placebo - Nipah Virus Infection | Phase 1 | Completed | Auro Vaccines LLC | 192 | 2020-02-18 | 2022-11-17 |
| Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults Inactivated Poliomyelitis Vaccine (IPV), E.coli Double Mutant Heat-Labile Toxin (dmLT) (adjuvant), Bivalent Oral Polio Vaccine (bOPV) - Polio | Phase 1 | Completed | PATH | 87 | 2020-01-22 | 2022-09-06 |
| Dose Escalating Study of Intramuscular Invaplex[AR-DETOX] Invaplex[AR-DETOX], Placebo - Diarrhea | Phase 1 | Completed | PATH | 58 | 2019-03-18 | 2021-07-29 |
| Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC) CssBA, dmLT - Diarrhea | Phase 1 | Completed | PATH | 50 | 2018-01-16 | 2021-01-06 |
| Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine cH8/1N1 LAIV, AS03-adjuvanted cH5/1N1 IIV, cH5/1N1 IIV - Influenza, Vaccine | Phase 1 | Completed | PATH | 65 | 2017-10-10 | 2021-02-21 |
| Phase 1 Novel Live Attenuated Serotype 2 Oral Polio Vaccine Study in Inactivated Polio Vaccine (IPV) Primed Adults Novel OPV2 candidate 1, Novel OPV2 candidate 2 - Poliomyelitis | Phase 1 | Completed | Pierre Van Damme | 30 | 2017-05-16 | 2021-02-04 |
| Shigella WRSS1 Vaccine Trial in Bangladesh Shigella sonnei Strain WRSS1 Vaccine, Placebo - Diarrhea | Phase 1 | Completed | PATH | 16 | 2017-02-23 | 2020-03-31 |
| Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge Strain Shigella sonnei 53G - Healthy | Phase 1 | Completed | PATH | 56 | 2016-09-12 | 2019-06-03 |
| A Study of a Vaccine for Pneumonia in Adults and Toddlers in Kenya PATH-wSP, Placebo - Pneumonia | Phase 1 / Phase 2 | Completed | PATH | 248 | 2016-08-10 | 2018-11-28 |
| Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults Adjuvanted MCV-5, Non-Adjuvanted MCV-5, Menactra® - Meningococcal Vaccines | Phase 1 | Completed | PATH | 60 | 2016-08-01 | 2021-06-09 |
| Safety and Immunogenicity Study of Trivalent P2-VP8 Subunit Rotavirus Vaccine in Adults, Toddlers and Infants Trivalent P2-VP8 Subunit Rotavirus Vaccine, Placebo - Healthy | Phase 1 / Phase 2 | Completed | PATH | 618 | 2016-02-15 | 2020-03-10 |
| A Study of a Seasonal Trivalent Split, Inactivated Influenza Vaccine Influenza vaccine, split inactivated, Placebo - Influenza, Human | Phase 1 | Completed | Institute of Virology, Vaccines and Sera, Torlak | 60 | 2015-11-01 | 2019-01-15 |
| Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) Trivalent Seasonal Influenza Vaccine, Placebo - Influenza, Human | Phase 1 | Completed | Institute of Vaccines and Medical Biologicals, Vietnam | 60 | 2015-11-01 | 2019-02-15 |
Showing 20 of 42. Sign in to see all of them.
Influenza, Human (9) · Dysentery, Bacillary (8) · Diarrhea (6) · Poliomyelitis (4) · Rotavirus Infections (3) · Escherichia coli Infections (2) · Pneumococcal Infections (2) · Bacterial Infections (1) · Cholera (1) · Digestive System Diseases (1) · Dysentery (1) · Enterobacteriaceae Infections (1) · Gastroenteritis (1) · Gastrointestinal Diseases (1) · Gram-Negative Bacterial Infections (1)
Vaccines (2) · 10-valent pneumococcal conjugate vaccine (1) · 13-valent pneumococcal vaccine (1) · 23-valent pneumococcal capsular polysaccharide vaccine (1) · AS03 adjuvant (1) · Adjuvants, Pharmaceutic (1) · Ciprofloxacin (1) · IOWH-032 (1) · Influenza Vaccines (1) · Krebs-Ringer HEPES bicarbonate solution (1) · Meningococcal Vaccines (1) · PHiD-CV vaccine (1) · Pentavac (1) · Poliovirus Vaccine, Inactivated (1) · Saline Solution (1)
United States (14) · Bangladesh (4) · India (3) · Kenya (3) · Russia (3) · South Africa (3) · Vietnam (3) · Belgium (2) · Canada (1) · China (1) · Dominican Republic (1) · Germany (1) · Netherlands (1) · Serbia (1) · The Gambia (1)
Clayton D Harro, MD, ScM (2) · Kathleen M Neuzil, MD, MPH (2) · Anthony Scott, MD (1) · Arlene Sena, MD (1) · Bruce G Weniger, MD, MPH (1) · Clayton Harro, MD (1) · Dang D. Anh, Ph. D (1) · Darin L Zehrung, BS (1) · David Bernstein, MD (1) · Ed Clarke, MD PhD (1) · Evelyn Hatzenbichler, PhD (1) · Goran Stevanovic, PhD (1) · Ho V Thang, MD, MSc (1) · Igor Victorevich (1) · Jeffrey Guptill, MD (1)
PMID 26432909, PMID 19545211, PMID 24374502, PMID 24533064, PMID 26065919, PMID 26296497, PMID 26865592, PMID 27567493, PMID 27591953, PMID 28483414, PMID 29239682, PMID 29534721, PMID 30120069, PMID 30337172, PMID 30473185, PMID 30797634, PMID 31174831, PMID 31630990, PMID 31757774, PMID 31843266, PMID 32251641, PMID 32734176, PMID 33288923, PMID 35536001, PMID 36146847, PMID 36533948, PMID 36746739, PMID 38218668, PMID 39852827, PMID 40132593, PMID 40152601, PMID 40818478, PMID 41576705
2017 (1), 2019 (1), U01AI053719 (1)